1. Home
  2. LPG vs DFTX Comparison

LPG vs DFTX Comparison

Compare LPG & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dorian LPG Ltd.

LPG

Dorian LPG Ltd.

HOLD

Current Price

$37.91

Market Cap

1.5B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.98

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LPG
DFTX
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
LPG
DFTX
Price
$37.91
$20.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$39.33
$38.50
AVG Volume (30 Days)
387.2K
2.0M
Earning Date
05-21-2026
05-04-2026
Dividend Yield
8.51%
N/A
EPS Growth
N/A
N/A
EPS
2.64
N/A
Revenue
$353,341,476.00
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.60
$14.62
52 Week High
$38.40
$26.25

Technical Indicators

Market Signals
Indicator
LPG
DFTX
Relative Strength Index (RSI) 64.37 49.51
Support Level $29.47 $16.37
Resistance Level $38.40 $26.25
Average True Range (ATR) 1.28 1.48
MACD 0.22 -0.13
Stochastic Oscillator 92.60 9.67

Price Performance

Historical Comparison
LPG
DFTX

About LPG Dorian LPG Ltd.

Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: